Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive agreement with Clinigen Group to manage the supply and distribution of AGAMREE® (vamorolone) in countries where the product ...

Pratteln, Switzerland Tuesday, January 7, 2025, 11:00 Hrs [IST] ...

Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive agreement with Clinigen Group to manage the supply and distribution of AGAMREE® (vamorolone) ...

Despite weathering significant criticism from lawmakers and patient groups over the steep cost of its rare disease med ...

2024 – Santhera Pharmaceuticals (SIX: SANN) announces that the Department of Health of Hong Kong, China, has approved AGAMREE® (vamorolone) for use in patients aged 4 years and older. The approval by ...

"DMD is a devastating condition affecting over 70,000 families in China, and until now, there had been no approved treatment option for patients," said Dario Eklund, CEO of Santhera. "We are delighted ...

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Santhera Pharmaceuticals Holding (SPHDF – Research Report) today and set a price target of CHF25.00. Discover top-rated stocks ...

Sperogenix exercised this option in July 2024 to include these territories in their license agreement. Santhera is supplying AGAMREE to Sperogenix for both the ongoing Early Access Program (EAP) and ...

China’s National Medical Products Administration (NMPA) has approved Santhera Pharmaceuticals’ AGAMREE (vamorolone), used to treat Duchenne muscular dystrophy (DMD) in patients aged four years ...

Pratteln, Switzerland, December 20, 2024 – Santhera Pharmaceuticals (SIX: SANN) announces that the Department of Health of Hong Kong, China, has approved AGAMREE® (vamorolone) for use in patients aged ...